FTC Lets King Buy Alpharma Now That Antitrust Problem Is Resolved – But New Embeda Delay Adds Risk To Acquisition
This article was originally published in The Pink Sheet Daily
Executive Summary
After FTC complaint, King opts to keep Avinza, and let patent-limited competitor go. But a new delay for key Alpharma product could hurt value of acquisition.
You may also be interested in...
Actavis’ MoxDuo: Can A Generic Firm Drive Growth With A Low-Dose Product?
Actavis aims to replace its Kadian pain franchise through a deal with QRxPharma for a fixed-dose combination of morphine and oxycodone.
Advisory Committee Sides With FDA: King/Acura's Acurox Fails To Prevent Abuse
The public forum did no favors for Acurox, as advisory committee members questioned whether adding niacin to oxycodone would really deter abuse.
Advisory Committee Sides With FDA: King/Acura's Acurox Fails To Prevent Abuse
The public forum did no favors for Acurox, as advisory committee members questioned whether adding niacin to oxycodone would really deter abuse.